Eylea (aflibercept intravitreal) / Bayer, Regeneron - LARVOL DELTA

SDZ-AFL: An Aflibercept Biosimilar. (PubMed, Clin Drug Investig) - "SDZ-AFL (SOK583A1; Afqlir®) is a biosimilar of the reference intravitreal aflibercept, a vascular endothelial growth factor inhibitor...The tolerability, safety and immunogenicity profiles of SDZ-AFL were similar to those of reference aflibercept. The role of reference aflibercept in the management of neovascular retinal diseases is well established, and SDZ-AFL provides an effective biosimilar alternative for patients requiring ophthalmic aflibercept therapy."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Intravitreal aflibercept alone versus combination with dexamethasone phosphate for diabetic macular edema: A randomized phase-2 clinical trial. (PubMed, Arq Bras Oftalmol) - "The addition of dexamethasone sodium phosphate to the standard intravitreal aflibercept regimen for diabetic macular edema can improve short-term structural and functional outcomes."

Clinical • Journal • P2 data • Diabetic Macular Edema • Ophthalmology

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report. (PubMed, Cureus) - "An 83-year-old man was referred to our clinic and diagnosed with type 1 macular neovascularization (MNV), with a previous treatment history of four doses of ranibizumab, 14 doses of aflibercept (2 mg), and two doses of faricimab...One week after subtenon triamcinolone acetonide (STTA) and topical dexamethasone, inflammation disappeared in the anterior chamber. In eyes with a history of IOI, careful attention is needed when switching to aflibercept 8 mg from another second-generation VEGF inhibitor, including faricimab."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Pain • Retinal Disorders • Wet Age-related Macular Degeneration

4FRONT-2: Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: 4D Molecular Therapeutics

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up. (PubMed, Clin Ophthalmol) - "Intravitreal aflibercept using a TAE regimen improved visual and anatomical outcomes of patients with type 1 CNV secondary to chronic CSC in long-term follow-up. Naive patients had a better visual outcome and a higher incidence of complete fluid resolution than PDT-treated patients."

Journal • Retinal Disorders

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema. (PubMed, Ther Adv Ophthalmol) - "What do the results mean? Often, patients with DME may find it difficult to keep up with the routine medical appointments that are required to maintain their vision.Findings showed that aflibercept 8 mg provided a similar level of improvement in vision to aflibercept 2 mg in people with DME but with fewer injections after 1 year of treatment.Treatment with aflibercept 8 mg may help to improve vision in these patients with fewer injections."

Journal • Review • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration. (PubMed, Jpn J Ophthalmol) - "Loading phase treatment with intravitreal aflibercept 8 mg appears to be effective for improving visual acuity and ameliorating exudative changes in eyes with nAMD. However, careful monitoring is required due to the potential development of IOI associated with retinal vasculitis."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis • Wet Age-related Macular Degeneration

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy (clinicaltrials.gov) - P4 | N=15 | Recruiting | Sponsor: Retina Consultants of Orange County | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2027 ➔ Aug 2027 | Initiation date: Nov 2024 ➔ Jul 2025 | Trial primary completion date: Mar 2026 ➔ Aug 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy. (PubMed, Sci Rep) - "Hypoautofluorescence, indicating macular atrophy was observed in 1 eye, and 1 eye developed transient visual loss at posttreatment. In terms of the rapid resolution of SRF and the improvement in VA, reduced-PDT combined with IVA can be a treatment option for PNV in the working-age population."

Journal • Retrospective data

Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Implementing our exit strategies, 68.75% of eyes achieved LTR across the two injection protocols. Age, disease subtype, baseline anatomical features, and yearly injection numbers may predict sustained remission and a longer time to experience recurrence."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management. (PubMed, Int Ophthalmol Clin) - "Epidemiologic data show variable incidence across agents, with brolucizumab demonstrating higher rates of inflammation compared with ranibizumab or aflibercept. Treatment includes corticosteroids and discontinuation of the offending agent, with rare cases requiring surgical intervention. As the therapeutic landscape expands, heightened awareness and standardized evaluation of postinjection inflammation are critical to improving safety and preserving vision."

Journal • Review • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis

Macular exudation associated with a racemose hemangioma, vasoproliferative tumor and Coats-like vasculopathy. (PubMed, Retin Cases Brief Rep) - "The unusual combination of uncommon retinal vascular abnormalities in the patient's right eye showed marked improvement following laser photocoagulation and anti-VEGF therapy. Racemose hemangioma exudation and abnormal retinal hemodynamics may have contributed to development of the vasoproliferative tumor and Coats-like vasculopathy. This case demonstrates that targeted treatment of exudation and vasoproliferation can provide significant visual improvement despite a patient's complex combination of retinal vascular abnormalities. (250/250)."

Journal • Cardiovascular • CNS Disorders • Oncology • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Innostellar Biotherapeutics Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: May 2029 ➔ Oct 2029

Enrollment closed • Trial completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Iatrogenic posterior retinal break from intravitreal anti-VEGF injection in a vitrectomized eye. (PubMed, Retin Cases Brief Rep) - "This case presents a potential complication in vitrectomized patients receiving intravitreal injections."

Journal • Diabetic Macular Edema • Hematological Disorders • Ophthalmology • Retinal Disorders

Significant Correlation Between Retinal Blood Flow and Oxygen Saturation During Intravitreal Aflibercept Treatment for Central Retinal Vein Occlusion. (PubMed, Transl Vis Sci Technol) - "In CRVO, venous oxygen saturation and MBR were significantly correlated. Measuring and evaluating retinal blood flow and oxygen saturation during treatment of CRVO eyes is recommended."

Journal • Retinal Disorders • Retinal Vein Occlusion

A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration. (PubMed, Expert Opin Biol Ther) - P3 | "This study compared efficacy, pharmacokinetics (PK), immunogenicity, and safety between AVT06, proposed biosimilar to reference product (RP) aflibercept (Eylea®), in participants with neovascular age-related macular degeneration (nAMD). Similar PK, immunogenicity, and safety profiles were also shown. ClinicalTrials.gov identifier is NCT05155293; ClinicalTrialsRegister.eu identifier is 2021-003651-42."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. (PubMed, Clin Ophthalmol) - "Aflibercept biosimilars demonstrated comparable efficacy and safety profiles to reference aflibercept in the treatment of nAMD. These findings suggest that biosimilars may serve as a cost-effective alternative without compromising patient outcomes."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration. (PubMed, Retina) - "Ocular blood flow significantly decreased 30 minutes post-injection in faricimab-, brolucizumab-, or aflibercept-treated eyes with nAMD. Brolucizumab-treated eyes showed a significantly greater reduction in choroidal blood flow than aflibercept-treated eyes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

PRISM: 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=215 | Recruiting | Sponsor: 4D Molecular Therapeutics | Trial completion date: Nov 2026 ➔ Jan 2031 | Trial primary completion date: Nov 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy. (PubMed, Int J Ophthalmol) - "Using topical nepafenac in combination with both systemic eplerenone, and intravitreal aflibercept may provide better results in the treatment of CSCR."

Journal • Retinal Disorders

Comparison of intraocular pressure elevation following intravitreal injection of 70 µl aflibercept 8 mg. (PubMed, Jpn J Ophthalmol) - "There was no additional increase in IOP 30 minutes after intravitreal injections when switching from 50 µl to 70 µl volumes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Predictive Role of Complete Blood Count-Derived Inflammation Indices and Optical Coherence Tomography Biomarkers for Early Response to Intravitreal Anti-VEGF in Diabetic Macular Edema. (PubMed, Biomedicines) - " CBC-derived inflammation indices and OCT biomarkers have prognostic value in predicting early response to anti-VEGF therapy in DME in terms of functional and anatomical outcomes. These findings could help identify poor responders and guide personalized treatment strategies."

Biomarker • Journal • Diabetes • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology

Increased macular atrophy area with photodynamic therapy over intravitreal aflibercept at 2-year follow-up of pachychoroid neovasculopathy. (PubMed, Jpn J Ophthalmol) - "The increase in the MA area and the decrease in the SFCT were greater in the rfPDT group than in the IVA group for PNV, suggesting that IVA may be preferred over rfPDT for PNV treatment."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Our results with the usage of faricimab (Vabysmo) in patients with wet AMD (SOE 2025) - "10 of them were treatment naïve and 13 patients were switched from Eylea. Our results show that Faricimab (Vabysmo ) is effective both in treatment naïve and switched patients with AMD. The inhibition of the two signal pathways in Vabysmo leads to quicker and effective reduction of intraretinal fluid in the macula and reduces CRT. The drug is also with long lasting effect which is achieved with less number of applications."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

OTX-TKI-2023-AMD-303: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov) - P3 | N=825 | Active, not recruiting | Sponsor: Ocular Therapeutix, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration